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Scanned ion beam therapy of lung tumors is severely limited in its clinical applica-
bility by intrafractional organ motion, interference effects between beam and tumor
motion (interplay), as well as interfractional anatomic changes. To compensate for dose
deterioration caused by intrafractional motion, motion mitigation techniques, such as
gating, have been developed. However, optimization of the treatment parameters is
needed to further improve target dose coverage and normal tissue sparing. The aim
of this study was to determine treatment-planning parameters that permit to recover
good target coverage for each fraction of lung tumor treatments. For 9 lung tumor
patients from MD Anderson Cancer Center (Houston, Texas), a total of 70 weekly
time-resolved computed tomography (4DCT) datasets, which depict the evolution of
the patient anatomy over the several fractions of the treatment, were available. Using
the GSI in-house treatment planning system TRiP4D, 4D simulations were performed
on each weekly 4DCT for each patient using gating and optimization of a single
treatment plan based on a planning CT acquired prior to treatment. The impact on
target dose coverage (V95%,CTV) of variations in focus size and length of the gating
window, as well as different additional margins and the number of fields was ana-
lyzed. It appeared that interfractional variability could potentially have a larger impact
on V95%,CTV than intrafractional motion. However, among the investigated parameters,
the use of a large beam spot size, a short gating window, additional margins, and
multiple fields permitted to obtain an average V95%,CTV of 96.5%. In the presented
study, it was shown that optimized treatment parameters have an important impact on
target dose coverage in the treatment of moving tumors. Indeed, intrafractional motion
occurring during the treatment of lung tumors and interfractional variability were best
mitigated using a large focus, a short gating window, additional margins, and three
fields.
Keywords: medical physics, radiotherapy, particle therapy, ions, treatment planning, moving targets, moving
organs
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1. INTRODUCTION
Treating moving targets, such as non-small cell lung cancer
(NSCLC) tumors, using photon radiation therapy has been inves-
tigated (1) and is being clinically used nowadays combined to
real-time tracking (2, 3). However, using heavy-ion scanned beam
therapy has shown many advantages compared to conventional
radiotherapy (4, 5) by reducing the number of fields, which have
to be used as well as the dose delivered to the organs at risk
(OARs) in the vicinity of the tumor. It also demands high precision
and accuracy when applied to moving tumors because of the
possible dose delivery errors induced by range shifts themselves
due to intrafractional motion, interfractional anatomic changes,
and patient misalignments (6, 7). This is why several motion
mitigation techniques, such as gating, rescanning, or tracking have
been developed and are still under development (8). Gating (9, 10)
is a technique which consists in turning the beam on when the
moving tumor reaches a precise motion state, in general, at the
end of exhalation while the tumor is the most stable. It has shown
great potential and has thus been successfully used in Japan in
ion beam therapy with passive absorbers for beam shaping (11–
13). Active scanned beam delivery introduces interplay effects
(14) and even though tumor motion mitigation techniques are
used, these effects can lead to non-conformal dose delivery. In
order to address specifically this problem, 4D treatment planning
systems (4DTPS) have been implemented (15, 16) and permit
to simulate the treatment of moving targets using gating while
also taking interplay effects into account. Nonetheless, treatment
parameters still have to be optimized to maximize motion mitiga-
tion obtained using gating. Several studies have been performed
to determine the influence of different parameters on the dose
delivery: Bert et al. (17) proposed to increase pencil beam overlap
to mitigate interplay effects as well as Steidl (18) and Richter
(19) whose studies displayed the effects of different lateral grid
spacing, isoenergy slice distance, focus size, and Bragg peakwidth.
In a combination gating and rescanning, Furukawa et al. (20)
proposed a method called phase-controlled rescanning, aiming
at compensating further the residual tumor motion within the
gating window. Rescanning was used as mitigation technique
by Knopf et al. (21), and the impact of the entry channel was
also investigated through different field scenarios. Target defini-
tion including tumor motion, size, and position (22), as well as
range-adapted margins, were discussed (15, 23–25) and imple-
mented (26). However, those studies concentrated on intrafrac-
tional motion compensation, meaning that the possible anatomic
variability between the time of the treatment planning CT and
treatment or also between fractions was not taken into account.
Simulations were, in general, restricted to a single 4DCT taken for
treatment planning. The purpose of this study was to investigate
which parameters could be isolated and optimized in order to
compensate correctly for both intrafractional tumor motion and
interfractional anatomic changes and/or patient misalignments.
To this end, in a cohort of patients with a time series of 4DCTs and
for different combinations of treatment and/or beam parameters,
one gating planwas optimized using the first weekly 4DCTof each
patient andwas forward calculated on the successive 4DCTs of the
weeks following treatment planning. Results were then compared
to determine the best configuration.
2. MATERIALS AND METHODS
2.1. Patient Cohort
Data from 9 NSCLC lung tumor patients from the MD Anderson
Cancer Center (MDACC) (27) were used to perform this study,
reaching a total of 70weekly 4DCTdatasets. Each 4DCTwas com-
posed of 10 3DCTs representing 10 different phase-based tumor
motion phases over the breathing cycle. End-exhale, referred to as
phase n° 5, was set as the reference state. Number of weeks,motion
amplitude, angles for single field and multiple fields calculations,
and clinical target volumes (CTVs) with and without additional
margins are listed in Table 1. The number of weekly 4DCTs per
patient varied between 6 and 10; each 4DCTwas treated as a single
fraction, with the first 4DCT as the planning CT. Most of the
patients have an average tumor motion below 5mm and only one
patient shows a tumor motion above 20mm (Patient 9).
2.2. Treatment Planning
2.2.1. Image Registration
Rigid registration of reference phases of each subsequent CT was
performed to mimic patient setup and alignment. Then non-rigid
registration was used between each 4DCT motion phase using
Plastimatch (28). For each patient, clinical target volumes (CTVs)
as well as OAR contours (esophagus, heart, and spinal cord) were
TABLE 1 | Description of the 9 NSCLC patients from MDACC (see Figure 1 for field angles illustration): patient number, number of weeks available, mean
motion amplitude and range, field angle for single field calculations (SFUD), field angles for multiple fields calculations (SFUD1, 2, and 3), volume of the
CTV, and volumes of the extended target: 3mm isotropic (I3), 3mm+3% range (R3), and combination of both (I3+R3).
Patient Weeks Motion (mm) Angles (°) Volumes (cc)
SFUD SFUD1 SFUD2 SFUD3 CTV I3 R3 I3 +R3
1 8 3:4 240 180 225 270 236 322 406 518
2 6 8:6 0 0 315 270 574 718 891 1057
3 9 10:1 0 270 315 0 161 213 335 409
4 8 3:3 225 180 225 270 676 819 925 1089
5 10 4:1 0 0 315 270 372 472 648 791
6 8 1:8 0 0 315 270 705 828 935 1072
7 7 1:6 180 180 225 270 124 172 253 322
8 8 4 180 180 225 270 45 65 102 133
9 6 23:5 180 180 225 270 125 164 203 250
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provided by physicians of MDACC for the first weekly 4DCT.
Lung contours were extracted from theweekly 4DCTs using an in-
house algorithm. Files containing vector fields (between the first
week and the following ones) obtained using deformable registra-
tion (29) were then used to propagate the previously mentioned
contours from the reference phase of the first weekly CT to the
reference phases of the following ones (16). Finally, vector field
files yielded by deformable registration applied on the 10 states of
each weekly 4DCT permitted to propagate the contours from the
reference state to the 9 other motion states.
2.2.2. Optimization and 4D Calculations
In this study, the technique used to mitigate motion was gat-
ing. All gating plans were simulated using 12C ions and the GSI
treatment planning system TRiP4D (16), based on TRiP98 and
modified to allow 4D-dose calculations. For each patient, plans
were initially optimized to the internal target volume (ITV) of the
first week’s CT using one unique planned dose of 8.1Gy(RBE).
Motion-related geometrical and range changes were considered
according to Graeff et al. (26). The generated raster scanning
plan was then used for all 4D calculations of the first week itself
and the following ones as well. It means that only one plan
was used per patient and that there was no replanning before
simulations of the fractions following the first optimized one.
In each case, the ITV was built using a combination of five
CTVs (26) from five different motion phases representing 25%
of the amplitude. The motion surrogate was defined accord-
ing to Lujan et al. (30), i.e., a sine to the power of 4 with a
unique period of 3.6 s. Only one starting phase (0°) was stud-
ied because, due to gating, beam delivery for different starting
phases is quickly synchronized after the first few spills of the syn-
chrotron accelerator, thus calculations yield very similar results
for different starting phases. As other fixed treatment parame-
ters, the distance between each raster position was set to 2mm
on each isoenergy slice (IES), and the distance between two
IESs was set to 3mm water equivalent using a ripple filter of
3mm (31).
2.2.3. Investigated Parameters
The impact of different treatment plan parameters on the dose
delivery was investigated using the field angles listed in Table 1.
First, using one single field (see column “SFUD” of Table 1 and
Figure 1) and ITV margins only, variations in focus size and
length of the gating window (GW) were performed. Three GWs:
11.9, 30, and 50% of the amplitude and three beam foci: 6, 10,
and 15mm (FWHM) were chosen as varying parameters. Two
configurations in particular were compared:
 LFSG: large focus (15mm) and short GW (11.9%),
 SFLG: small focus (6mm) and long GW (50%).
As a second part, using the same single field angles, different
planning target volumes (PTV) created by adding additional mar-
gins to the originally optimized plans were also investigated as
another solution to recover good target coverage. Three different
cases were studied: 3mm isotropic margins (geometrical, referred
to as I3), 3mm+ 3% range margins (water equivalent, referred
FIGURE 1 | Field angles used (see Table 1).
FIGURE 2 | Different margins cases used in the second part of the
study. From the left to the right, configurations displayed are referred to as
ITV, I3, R3, and I3+R3.
to as R3), and combination of both (referred to as I3+R3, see
Figure 2). Resulting dose deliveries were compared to the results
obtained using ITVmargins only. Combinations of GWs and foci
(same 3 foci and 3 GWs than in the previous paragraph) were
again investigated in each case to observe the impact of additional
margins on the range. Finally, still using the 9 possible GW/focus
combinations, the number of fields was varied from 1 to 3 (see
Table 1 for field angle values, columns “SFUD1” to “SFUD3”
and Figure 1) using only ITV margins first and then using the
additional PTV margins which had been determined to yield the
best results in the second section of this chapter, resulting in the
following cases:
 SFITV : single field to ITV only,
 SFPTV : single field to the isotropic/range margins (same as
I3+R3),
 2FITV : ITV only but with 2 fields,
 2FPTV : same margins as SFPTV but with 2 fields,
 3FITV : ITV only but with 3 fields,
 3FPTV : same margins as SFPTV but with 3 fields.
2.3. Data Analysis
In each case, the dose distribution of each week was obtained
by accumulating the dose delivered to each motion state on the
reference phase of the 4DCTs using state-to-state non-rigid vec-
tor fields. To estimate the impact of each previously described
parameter and configuration on the dose delivery, the following
two indexes were used:
 Target coverage, V95: volume of the target to which 95% of the
planned dose is delivered, representing the quality of target dose
coverage, unit is percentage of volume,
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 Conformity number (CN) (32): allowing a quantification
of the high-dose regions inside and outside the tumor
(the higher, the better) and defined by:
CN =
V95%;CTV
VCTV
 V95%;CTVV95%
(1)
where V95%,CTV is the V95 value defined above, VCTV the vol-
ume of the CTV, and V95% the total volume which receives at
least 95% of the dose.
The main focus of this study is the impact of treatment plan
parameters on dose delivery. All dose calculations were computed
for weekly simulations but not for the cumulated total treatment
regime. Therefore, OAR limit dose values from the literature were
not taken into account but are used only a general indicator of
plan quality. This study aims at determining clearly the effect
of the investigated parameters on the decreased quality of the
dose delivery due to both interfractional anatomy changes and
intrafractional tumor motion. In each case, a Wilcoxon signed-
rank test was performed using a level of significance of 0.05 to
estimate the difference between two sets of datapoints. In the case
of samples containing more than 10 values, the p-value (p) was
computed using the obtained z-score (z).
3. RESULTS
All simulations were performed on the weekly 4DCTs with a
planned dose of 8.1Gy(RBE), which corresponds to a single field
dose as reported by NIRS (5) according to LEM IV (33). In all the
following figures, the average value (marker), the median value
(horizontal bar in the box), the 25th and 75th percentile, and the
total range of all values are given. In some cases, different types of
simulations were studied and referred to as
 3D0 simulations: planned, static dose simulations using the first
weekly CT (week 0 in reference phase),
 4D0 simulations: 4D dose simulations using the first weekly
4DCT (week 0) and the same plan than 3D0 simulations, which
contains the effects of intrafractional motion only,
 4DN simulations: 4D dose simulations using all the following
weekly 4DCTs (weeks 1 to 5–9) and the same plan than 3D0
simulations, which contains the effects of both intrafractional
motion and interfractional patient anatomic changes.
3.1. Beam Focus and Gating Window
Figure 3 and Table 2 show V95 and CN for different GW/focus
combinations, for all patients. 3D simulations show good results
for all focus sizes, with slightly better target coverage and slightly
worse conformity for the largest focus (p< 0.05). The 4D0 simu-
lations show the effect of intrafractional tumor motion on target
dose coverage:V95 decreases with a large variability for the smaller
focus sizes. A large focus and gating window of 30% restores target
coverage to the static values. CN, however, shows no significant
(p< 0.05) change with GW or focus but decreases slightly com-
pared to static calculations. 4DN results of the following weeks
permit to investigate the effect of both interfractional changes but
also intrafractional motion. Comparison to 4D0 shows a similar
trend for GW and focus size, but the interfractional changes
result in approximately 10 worse target coverage and CN.Without
margins, adequate target coverage cannot be reached for any
simulation with a small focus/large GW and less for than half
with a large focus/small GW. Dose cuts for these combinations
are displayed for the 7th weekly CT of patient 3 in Figures 4A–F,
respectively.
3.2. Margins
Not surprisingly, margins are necessary to achieve target coverage
including interfractional changes. Figure 5 and Table 3 show the
impact onV95 and CN for ITV only (ITV), ITV+ 3mm isotropic
margins (I3), ITV+ 3%+ 3mm range margins (R3), and a com-
bination of both margins (I3+R3), respectively. 3D0 simula-
tions reveal that range margins have a larger impact on CN than
FIGURE 3 | Impact of the focus and the GW on V95 and CN. Each 3D0 and 4D0 bar is composed of 9 points and each 4DN bar of 61 points.
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TABLE 2 | Results of the influence of the focus and gating window on V95 and CN.
Simulations Focus (mm) Gating window (%) V95 (%) CN V95 >95% (%)
Min. Mean Max. Min. Mean Max.
3D0 6 – 96.6 98.9 99.9 0.57 0.72 0.88 100
10 – 96.8 99.1 99.9 0.55 0.68 0.84 100
15 – 96.7 99.2 99.9 0.53 0.64 0.82 100
4D0 6 50 62.6 86.8 95.4 0.45 0.63 0.81 11.1
30 81.4 91.0 97.0 0.52 0.66 0.83 33.3
11:9 84.9 93.2 97.9 0.53 0.67 0.83 55.6
10 50 74.8 93.0 98.7 0.53 0.64 0.83 66.7
30 86.5 95.9 99.3 0.55 0.66 0.83 66.7
11:9 94.0 97.9 99.6 0.55 0.66 0.83 88.9
15 50 88.0 96.5 99.8 0.52 0.62 0.80 77.8
30 95.4 98.5 99.8 0.53 0.63 0.79 100
11:9 97.4 99.3 99.9 0.52 0.63 0.79 100
4DN 6 50 42.8 77.7 94.3 0.15 0.48 0.79 0
30 50.2 80.6 95.4 0.14 0.50 0.80 1.6
11:9 55.4 82.5 95.8 0.15 0.51 0.81 4.9
10 50 48.4 83.5 96.8 0.16 0.50 0.80 11.5
30 56.7 85.5 98.2 0.15 0.51 0.80 27.9
11:9 61.8 87.4 98.5 0.17 0.52 0.80 29.5
15 50 60.6 87.9 98.8 0.16 0.50 0.79 37.7
30 63.9 89.8 99.1 0.16 0.51 0.79 41
11:9 67.5 90.9 99.3 0.17 0.51 0.79 42.6
isotropic ones (p< 0.05), as shown in Table 3. Calculations on
the planning CT (4D0) show a minor but significant impact from
increased margins. CN is degraded through increasing margins
(p< 0.05). Interestingly, the isotropic margins show a comparable
effect to range margins in the 4D calculations, as opposed to 3D.
As a consequence, also the combined margins further decrease
CN. The margin size shows a considerable impact on interfrac-
tional changes, decreasing the target coverage gap between 4D0
and 4DN from 10 to 2% with the I3+R3 combination. Range
margins are more effective than isotropic margins (p< 0.05). The
same trend can be observed for CN, which decreases with margin
size (p< 0.05), but reaches nearly the level of 4D0 for I3+R3.
The percentage of successful fractions (V95> 95%) reaches 68.7%
on average for I3+R3, but 90.2% for the I3+R3 for the large
focus/small GW. Exemplary dose distributions (using the 1st and
again the 7th weekly CTs of patient 3) using the largest focus and
the shortest GWcombined to ITVmargins (ITV), and to ITVplus
I3, R3, and I3+R3 are displayed in Figures 4D–O, respectively.
3.3. Number of Fields
Figure 6 and Table 4 show the impact of the number of fields
for the ITV only and for ITV with I3+R3, subsequently called
PTV. Again, 3D0 simulations yield excellent target coverage, but
multiple fields slightly improve CN for the ITV only, while they
degrade CN for PTV margins (p< 0.05, see Table 4). Using
more than one field helps to mitigate intrafractional motion, with
increasing V95 for both ITV and PTV margins (p< 0.05). PTV
margins improve target coverage but considerably decrease CN
(both p< 0.05). The same effect can be observed for 4DN, where
more than one field and PTV margins significantly increase V95.
The conformity can essentially be restored to the static or 4D0
value using PTV margins and three fields. For this combination,
more than 80% of simulations lead to adequate target coverage,
and 93.4% for the small focus/large GW, see also Figure 6. A
dose distribution example using week 6 of patient 3 from single
field ITV simulations (SFITV) and single field, 2 fields, and 3
fields PTV simulations (SFPTV, 2FPTV, and 3FPTV) are shown
in Figures 4D–F and 7A–F, respectively.
3.4. Tumor Motion and Size Dependence
The influence of the motion magnitude on V95 is displayed in
Figure 8A. In case of the green combination (small focus, long
GW, ITV, and one field), patients with a small motion (<6mm)
show an averageV95 of 85%, as opposed to 65% for patients with a
large motion. This difference of 20% is reduced to 3% if a large
focus, a small GW, PTV margins, and 3 fields are used, which
also yields mean V95> 95% for both groups. Dependence of CN
to the size is shown in Figure 8B. Patients with a smaller tumor
(<200 cc) show mean CN of 25 and 16% lower than large tumors
(>200 cc).
4. DISCUSSION
In this study, a time series of 4DCTs of lung cancer patients
was investigated for inter- and intrafractional effects of motion,
anatomic changes, and setup errors. Most studies of particle ther-
apy for moving targets focus on 4DCTs at a single time point,
assuming nearly perfect treatment conditions. In this respect, the
findings of this study offer highly important, previously unstudied
information for a more clinically realistic scenario.
4.1. Beam Focus and Gating Window
Results show that the larger the focus and the shorter the GW,
the better V95, meaning that intrafractional motion mitigation is
more effective using a large focus and a short GW, as illustrated in
Figure 4. Only the volume of the target (see Table 1 and Figure 8)
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FIGURE 4 | Dose distributions of patient 3 using different weekly CTs. Pink contours represent the CTV (week 6). Cases (A–C) and (D–F) are obtained using
the SFLG and the LFSG configurations, respectively, simulations (week 6). Cases (A–F) are obtained using the SFLG and the LFSG configurations, respectively, with
ITV margins only. Examples (G–P) are obtained using the LFSG configuration and 3mm isotropic margins, 3mm+3% range margins, and the combination of both
previous margins, respectively.
seems to have a direct impact on CN: CN values yielded for
simulations done with larger targets (patients 1, 2, 4, 5, and 6)
are higher than values obtained for simulations done with smaller
ones (patients 3, 7, 8, and 9); that can be observed in Figure 8
(and especially for the presented cases with ITV margins only).
Thus, GW and focus do not show a significant influence on CN,
which does not have a particular behavior regarding those param-
eters and is more patient specific: only patient 9 showed large
weekly CN variability (range= 0.3) over the different GW/focus
configurations compared to all other patients with a range< 0.1
[more details in Brevet (34)]. Thus, although V95 increases using
a large focus and a short GW, the total volume to which 95% of
the planned dose is delivered increases as well, i.e., OARs in the
vicinity of the tumor are irradiated. In both studies by Steidl (18)
and Richter (19), a larger focus permits to obtain better results
in terms of target coverage, which is in agreement with what has
been observed here. However, while a decreasing CN is obtained
with increasing focus size in the study by Steidl (18), this behavior
is not present in the study by Richter (19) and here. This can be
explained by the fact that Steidl (18) used a different CN, which
integrates the dose values obtained in all the voxels of the CTV
and thus ignores the high interplay dependency of V95, the latter
being itself the main component of the here used CN. Richter
(19) shows that CN is decreasing with larger foci only for static
cases (a behavior which can be also observed for static cases in
Figure 3), while it is more patient specific for cases with motion
and tends to converge on values obtained with static cases. The
same behavior was observed in the study by Brevet (34): weekly
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FIGURE 5 | Impact of additional margins on V95 and CN: ITV (ITV margins only), I3 (3mm isotropic margins), R3 (3mm+3% range margins), and
I3 +R3 (3mm isotropic + 3mm+3% range margins). Each 3D0 bar is composed of results obtained using all 9 patients and 3 foci, representing 27 points, and
each 4D0 and 4DN bar are composed of results obtained using all 9 patients, 3 foci, and 3 GWs, representing 81 and 549 points, respectively.
TABLE 3 | Results of the influence of ITV margins (ITV), 3mm isotropic margins (I3), 3mm+3% range margins (R3), and a combination of the two last ones
(I3 +R3) on V95 and CN.
Simulations Margins V95 (%) CN V95 >95% (%)
Min. Mean Max. Min. Mean Max.
3D0 ITV 96.6 99.1 99.9 0.53 0.68 0.88 100
I3 95.9 98.8 100 0.45 0.68 0.87 100
R3 96.7 99.4 100 0.37 0.51 0.72 100
I3+R3 96.2 99.1 100 0.34 0.53 0.73 100
4D0 ITV 62.6 94.7 99.9 0.45 0.64 0.83 66.7
I3 76.5 95.9 100 0.36 0.53 0.73 70.4
R3 73.4 96.3 100 0.35 0.50 0.70 74.1
I3+R3 77.2 96.6 100 0.29 0.42 0.62 75.3
4DN ITV 42.8 85.1 99.3 0.14 0.50 0.81 21.9
I3 57.8 90.5 99.7 0.15 0.46 0.75 40.4
R3 56.6 92.8 100 0.18 0.45 0.75 56.3
I3+R3 62.8 94.8 100 0.17 0.39 0.67 68.7
Each margins case of the 3D0 calculations was done using the 3 foci described previously. In the case of 4D0 and 4DN values, the 9 possible focus/GW combinations presented
previously were used.
results of each patient show that CN is patient and week specific
and that no discernable trend for focus or GW can be found. As a
global result, CN is slightly higher for larger foci, but when studied
separately for each patient and each week, CN values do not show
a systematic behavior. It can also be noticed that the focus size
has a much more significant influence on the results compared to
gating window. This is due to the size of the largest focus (15mm),
which is larger than the tumor motion for patients 1–8 or similar
to the tumor motion for patient 9 (see Table 1). Hence, it is much
easier to cover the moving tumor using this large focus. As using
a small GW can increase treatment time considerably, this setting
should be adjusted patient specifically.
Interfractional changes tend to dominate intrafractional ones,
which can be reliably mitigated with gating and a large focus.
The case shown in Figure 4 illustrates this (cf. Figures 4B,E), but
also the dominant cause for interfractional dose errors: consider-
able change in range to the target. Though this depends on the
chosen entry channel, Figures 4C,F show an extreme overshoot
compared to the planned treatment dose. This is an extreme case,
though, with considerable dose to OARs. On average, the impact
is less severe, as can be seen by CN being restored nearly to
the planned static value for multiple fields and large margins.
An analysis of individual OARs and dose constraints would be
necessary for more specific conclusions.
4.2. Margins
For intrafractional motion, Knopf et al. (25) and Albertini
et al. (35), using different sorts of margins, confirmed that
margins permit indeed to compensate efficiently for tumor
motion. Here, additional margins to a range ITV were studied
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FIGURE 6 | Impact of different numbers of fields on V95 and CN: 1, 2, and 3 fields with ITV (ITV margins only) and PTV (3mm isotropic + 3mm+3%
range margins). Each 3D0 bar is composed of results obtained using all 9 patients and 3 foci, representing 27 points, and each 4D0 and 4DN bar are composed of
results obtained using all 9 patients, 3 foci, and 3 GWs, representing 81 and 549 points, respectively.
TABLE 4 | Results of the influence of ITV and PTV margins and of different numbers of fields on V95 and CN.
Simulations Margins Fields V95 (%) CN V95 >95% (%)
Min. Mean Max. Min. Mean Max.
3D0 ITV 1 96.6 99.1 99.9 0.53 0.68 0.88 100
2 98.9 99.7 100 0.55 0.72 0.88 100
3 99.0 99.7 100 0.56 0.73 0.90 100
PTV 1 96.2 99.1 100 0.34 0.53 0.73 100
2 99.5 99.9 100 0.29 0.47 0.64 100
3 99.9 100 100 0.30 0.49 0.69 100
4D0 ITV 1 62.6 94.7 99.9 0.45 0.64 0.83 66.7
2 80.9 97.6 100 0.53 0.69 0.87 82.7
3 81.4 97.5 99.9 0.54 0.71 0.88 84
PTV 1 77.2 96.6 100 0.29 0.42 0.62 75.3
2 84.0 98.8 100 0.29 0.45 0.63 92.6
3 93.3 99.0 100 0.29 0.48 0.68 93.8
4DN ITV 1 42.8 85.1 99.3 0.14 0.50 0.81 21.9
2 51.9 88.1 99.5 0.23 0.59 0.87 29.1
3 48.2 87.3 99.7 0.26 0.62 0.87 30.1
PTV 1 62.8 94.8 100 0.17 0.39 0.67 68.7
2 65.8 96.8 100 0.21 0.44 0.70 81.2
3 65.8 96.9 100 0.26 0.48 0.74 82.5
Each margins case of the 3D0 calculations was done using the 3 foci described previously. In the case of 4D0 and 4DN values, the 9 possible focus/GW combinations presented
previously were used.
to recover misdosage from the interfractional changes. Figure 5
shows improving results when the irradiated volume is extended.
Sorted by increasing order, isotropic, range, and combined
isotropic/range margins yield better target coverage, for both 4D0
and 4DN simulations: V95 and CN are sensitive to additional
ITV-PTV margins. V95 improves indeed significantly in terms
of distribution range and mean value. And even though the
effects of interfractional changes can still be observed for 4DN
simulations (low minimal V95 value), using a combination of
additional isotropic and range margins permits to increase the
fraction of successful fractions from 21 to nearly 70%. It means
that combining those two margins to extend the irradiated region
improves coverage of the possible anatomic changes from fraction
to fraction. CN, however, reduces due to some additional dose
delivered in the vicinity of the target volume. This can be observed
in Figures 4D–O: V95 is improved but the irradiated volume
outside the tumor clearly increases gradually as more additional
margins are used.
Figures 4D–F,M–O showhowmargins can allow dose recovery
in the tumor for a patient with severe intra- and interfractional
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FIGURE 7 | Dose distributions of patient 3 using different weekly CTs. Pink contours represent the CTV. First column displays 3D0 simulations, second
column 4D0 simulations, and the third one 4DN simulations using week 6. Cases (A–I) are obtained using the LFSG configuration combined to isotropic and range
margins and one, two, and three fields, respectively.
FIGURE 8 | Influence of motion magnitude on V95 tumor size on CN, using two different treatment configurations. The red configuration represents
simulations done using one field, a focus of 6mm, a 50% GW, and ITV margins only, and the green configuration represents three fields, a focus of 15mm, a 11.9%
GW, and PTV margins (3mm isotropic+ 3mm+ 3% range margins). For the left graph (A), bars representing tumors whose motion is lower than 6mm are
composed of 21 points (three patients, 21weeks), while bars representing tumors whose motion is larger than 6mm are composed of 49 points (six patients,
49weeks). In the case of the right graph (B), small tumor (<200 cc) bars are composed of 30 points (four patients, 30weeks) and big tumor (>200 cc) bars are
composed of 40 points (five patients, 40weeks). See Table 1 for more details about patients.
motion. In this case, the combination of range and isotropic
margins permits to reach a mean V95 value 20% higher com-
pared to the use of ITV margins only. Thus, the conclusions of
Knopf et al. (25) and Albertini et al. (35), stating that intrafrac-
tional motion can be mitigated by the use of margins, can be
extended by the fact that margins also allow to compensate
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efficiently for dose delivery deterioration caused by interfractional
changes. However, it is also clearly visible that OARs, such as
the spinal cord and the ipsilateral lung, are irradiated with a
higher dose.
4.3. Number of Fields
To dilute the dose to OARs, multiple fields are typically employed
and have also been shown to help mitigate intrafractional motion
Knopf et al. (21) through an enhanced rescanning effect. Com-
binedwith ITVmargins only,multiple fields significantly improve
V95 and CN. Using two or three field did not result in an improve-
ment in target coverage. This can be explained by the lack of
an automatic optimization method for field directions. Using a
generic, geometric approach to choose field directions, it became
more likely with three fields to pass through tissue heavily affected
by interfractional changes. Thus, a field affected, e.g., by a range
shift would deteriorate target coverage instead of further improv-
ing it. This effect was minor and not significant, though. On the
other hand, conformity could be further improved by distributing
dose to more entry channels, which decreases V95 outside of the
target and thus improvesCN. This shows that choosing field direc-
tions carefully to avoid regions that are likely affected by interfrac-
tional changes would result both in good target coverage and good
CN. Added PTVmargins as expected improve the results further.
V95 average values for 4DN simulations tend to converge to the
values obtained for 4D0 simulations, showing that interfractional
changes are almost completely mitigated. Outliers remain with
an inadequate target coverage, but more than 90% of successful
fractions become possible. CN is however drastically reduced due
to the extended irradiated volume, which is now partly composed
of normal tissue from the surrounding OARs.With the remaining
difference of V95 between 4D0 and 4DN of 1.2% (range 0–21%),
interfractional changes appear to be sufficiently compensated.
Dose distributions in Figures 7A–I illustrate the great advantage
of using three fields combined with additional margins. It allows
obtaining a conformal dose distribution, with a target which is
completely and homogeneously covered, and reduced high-dose
regions outside the tumor. Again, field directions can be chosen
differently to avoid or decrease further the irradiated volume of
lung visible in Figures 7G–I.
This study has some limitations. The focus was set on identi-
fying relevant planning parameters. To identify these, most plans
would not be clinically valid or deliverable, but are helpful in
showing the effect of isolated technical parameters. A further issue
is the (unavoidable) use of deformable image registration to both
propagate contours across the different CTs and phases and also to
accumulate dose in the reference phase of each CT. Careful quality
insurance was performed, using checker-board and false-color
images as well as inspection of the resulting vector fields, with
resulting errors to be expected in the order of 2mm(36). Tomimic
patient setup, CTswere rigidly registered against each other, which
might be more accurate than positioning with orthogonal X-rays,
so that additional margins would be required. Finally, though
serial 4DCT data was available, each 4DCT represented only a
single breathing cycle. Variable breathing cycles could be studied
using synthesized MR/CT data (37).
5. CONCLUSION
The aim of this study was to identify optimized treatment plan-
ning parameters in order to compensate for dose delivery deterio-
ration caused by intrafractional tumor motion and interfractional
variability. It was found that the use of a large focus (15mm,
FWHM), a short gating window (11.9% of themotion amplitude),
ITV-PTVmargins (3mm isotropic+ 3%+ 3mm rangemargins),
and 3 fields yielded the best results in terms of target dose cover-
age. Less than 6% of fractions remained below 95%. In conclusion,
in this first study combining state-of-the-art 4D dose calculation
with serial 4DCTdata, a combination of these parameters together
with careful choice of field directions permits safe fractionated
target dose coverage for NSCLC patients treated with 12C ions.
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